Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma

NCT00829465 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

DRUG: Licartin
PROCEDURE: Transcatheter arterial chemoembolization

Sponsor

Eastern Hepatobiliary Surgery Hospital